Singapore markets closed

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.3300-0.0400 (-2.92%)
At close: 04:00PM EDT
1.3300 0.00 (0.00%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3700
Open1.3800
Bid1.3200 x 1800
Ask1.3500 x 900
Day's range1.3300 - 1.4500
52-week range0.3600 - 1.9200
Volume1,377,138
Avg. volume2,522,898
Market cap194.691M
Beta (5Y monthly)-0.20
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date28 Apr 2014
1y target estN/A
All
News
  • GlobeNewswire

    Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

    --Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise-- --Company to present this month at upcoming American Association of Clinical Endocrinology annual meeting and GLP-1 Based Therapeutics Summit-- --Company to host conference call and webcast today at 8:00

  • GlobeNewswire

    Veru to Present at the GLP-1 Based Therapeutics Summit

    MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA. Presentation details: Advancing Enobosarm, An Oral Novel S

  • GlobeNewswire

    Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

    MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 second quarter financial results and to provide a business update. The audio webcast wi